Amphastar Pharmaceuticals is a specialty pharmaceutical company that focuses on developing technically-challenging injectable and inhalation products. In addition to its marketed products, the company has a pipeline of 21 generic and proprietary product candidates in various stages of development which target a number of indications.
Exited via Initial Public Offering (NASD: AMPH)
Exited via Initial Public Offering (NASD: AMPH)
Employees: 1001-5000
Founded date: 1996
Investors 2
| Date | Name | Website |
| - | W Capital ... | wcapgroup.... |
| - | YFY Biotec... | tgbfund.co... |
Mentions in press and media 22
| Date | Title | Description |
| 24.07.2026 | Trump's Generic Drug Tariffs: U.S. Onshoring Push Faces Steep Challenges | U.S. faces major generic drug tariff changes. Trump announced duties up to 200% on imported generics. A two-year window encourages domestic manufacturing. This policy aims to onshore critical drug production. Industry concerns are high. Gen... |
| 22.07.2026 | Trump’s generic drug tariffs: What they could mean for medicine prices, manufacturers and supply | Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details r... |
| 17.06.2026 | Naloxone Nasal Spray Gets Third OTC Brand as FDA Approves Rextovy by Amphastar | By Chase Fiorini Published: Jun 17 2026, 12:00 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 29.12.2021 | Amphastar Pharmaceuticals : Receives FDA Tentative Approval for Vasopressin | Amphastar Receives FDA Tentative Approval for Vasopressin December 29, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / December 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FD... |
| 09.11.2021 | Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 - Form 8-K | Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 Reports Net Revenues of $112.2 Million for the Three Months Ended September 30, 2021 RANCHO CUCAMONGA, CA - November 8, 2021 - Amphastar Pharm... |
| 09.11.2021 | Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 | Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 November 8, 2021 Reports Net Revenues of $112.2 Million for the Three Months Ended September 30, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / Nove... |
| 09.11.2021 | Presentations | Corporate Presentation November 2021 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management's current expectations and assumptions and on infor... |
| 09.11.2021 | Financial Documentt | Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021 August 9, 2021 Reports Net Revenues of $101.7 Million for the Three Months Ended June 30, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 9, 2021 /... |
| 28.10.2021 | Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8th, 2021 | Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8th, 2021 October 28, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that ... |
| 09.09.2021 | Amphastar Pharmaceuticals : Wells Fargo Presentation | 2021 Wells Fargo Virtual Healthcare Conference September 9, 2021 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management's current expectations ... |
Show more